


GLP-1 RA availability aspects - Sanofi

JUKKA WESTERBACKA, MD, PHD

Head of Medical, Established Products franchise, GenMed GBU



Sanofi's GLP-1 RA - once-daily product with distinctive characteristics

1st generation

GLP-1 RA

Once-daily administration

GetGoal program

- Demonstrated efficacy & safety in a broad range of T2D patients¹⁻¹²

Efficacy

- Modest effect on HbA_{1c} & weight¹⁻¹² (relative to 2nd & 3rd generation GLP-1 RAs)

CV safety

- Favorable safety/tolerability profile with proven cardiovascular safety¹³

EU Marketing Authorisation 2013

- Indicated for treatment of adults with T2D, with OADs ± basal insulin

No indication for obesity


- No indication for obesity, only for T2D

Post-prandial predominant effect

- Differentiated effect on gastric emptying & PPG reduction vs other GLP-1 RAs

Clinical practise have shifted away from daily to weekly GLP-1 RAs

Once-daily GLP-1RA represent 3% of Europe¹ GLP-1 RA usage, as weekly products dominate the market



Date	Daily GLP-1	Weekly GLP-1
Q1'2021	21%	79%
Q1'2024	3%	97%

Sanofi's GLP-1 RA availability conclusion



Clinical practise trends have led to minimal use of daily GLP-1 RAs

Daily GLP-1 RA is a part of our fixed ratio combination (FRC) with basal insulin that proves to offer a more optimal usage profile and better patient outcomes for patients with Type 2 diabetes

- Based on current information, no supply chain shortages of FRC projected in 2024

Continuous monitoring of market demand and supply situation is managed via one integrated system

- Weekly and monthly processes in place to escalate to a cross-functional team and activate counter-measures if needed